Navigation Links
Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease
Date:10/27/2008

Oral 5-Aminosalicylates Will Continue to be Used in Early Lines of Therapy, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade is currently the leading biologic for Crohn's disease, but Abbott/Eisai's Humira will soon become the first-choice among biologics.

Patient-level claims data indicate that Remicade currently captures a larger share of Crohn's disease patients on every line of therapy than Humira. However, 56 and 65 percent of surveyed gastroenterologists and primary care physicians say that, over the next two years, they will increase their use of Humira on the first and second lines of therapy, respectively. This shift will occur because Humira is easier to use--it can be self injected in the privacy of one's home versus having to go to the physician's office as is the case with Remicade which is administered intravenously. In addition, both gastroenterologists and primary care physicians say they will increase their use of Humira as a maintenance therapy.

According to interviewed experts, physicians are increasingly moving patients to biologics early in treatment.

"Moving up in lines of therapy means an expanded potential patient population for these agents," stated Michael Malecki, Ph.D., analyst at Decision Resources. "Because biologics are much more expensive than conventional agents, the trend of using them earlier in therapy will result in a net market expansion in terms of dollars."

The new report entitled Treatment Algorithms in Crohn's Disease also finds that oral 5-aminosalicylates will continue to be used in early lines of therapy for patients with mild disease. Among oral 5-aminosalicylates, Shire's Lialda has more convenient dosing. Because of this clinical advantage, surveyed physicians indicated that they intend to move patients to Lialda from both Procter & Gamble/Giuliani's Asacol and Shire/Ferring/Nisshin/Kyorin Seiyaku's Pentasa over the next two years.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

The reports can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst and are welcome to attend our upcoming webinar entitled Biologics Penetration of Early Lines of Therapy in Psoriasis, Crohn's and Rheumatoid Arthritis: Implications for Existing and Emerging Brands. The webinar will be held on Wednesday, November 19, 2008 at 10 a.m. EST. For more information, please contact Natalia Morales at 781.296.2691 or e-mail at nmorales@dresources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
2. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
3. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
4. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
5. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
6. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
7. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
8. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
9. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
10. Pill Equals Injection in Preventing Clots After Hip Replacement
11. Its Probably Time to Replace Your Vehicles Cabin Air Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology: